E-therapeutics Plc
ETXPF · OTC
1/31/2024 | 1/31/2023 | 1/31/2022 | 1/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.36 | 0.41 | -0.24 | -0.68 |
| FCF Yield | -11.66% | -7.85% | -7.20% | -7.46% |
| EV / EBITDA | -5.51 | -7.90 | -15.58 | -10.11 |
| Quality | ||||
| ROIC | -51.86% | -20.49% | -28.57% | -26.43% |
| Gross Margin | 100.00% | 100.00% | 74.37% | 72.82% |
| Cash Conversion Ratio | 1.11 | 0.98 | 0.97 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -20.85% | 2.95% | 2.19% |
| Free Cash Flow Growth | -35.56% | 29.82% | -150.01% | -75.26% |
| Safety | ||||
| Net Debt / EBITDA | 1.45 | 3.38 | 1.51 | 4.01 |
| Interest Coverage | 0.00 | -445.17 | -1,283.11 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -441.76 | -154.26 |